Trial Profile
Protection of saxagliptin tablets to pancreatic function on new diagnosed type 2 diabetes with continuous subcutaneous insulin infusion (csii)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Jan 2017
Price :
$35
*
At a glance
- Drugs Saxagliptin (Primary) ; Insulin; Metformin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 01 Dec 2016 Primary endpoint has been met. (Function of islet beta cell)
- 01 Dec 2016 Results published in the Diabetes Therapy
- 01 Dec 2016 Status changed from recruiting to completed.